Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for

Updated 06/21/2024

Status Completed

Clinical Trial Summary

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma of the Bladder
Carcinoma
Metastatic Bladder Cancer
Non-Transitional Cell Carcinoma of the Urothelial Tract
Small Cell of the Bladder
Squamous Cell Carcinoma of the Bladder
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT03430895
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	January 31, 2018
Completion date	February 10, 2021

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02028442` - Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients	Phase 1/Phase 2
	Completed	`NCT01454089` - A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer	Phase 2
	Recruiting	`NCT06138561` - Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
	Terminated	`NCT04887831` - Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab	Phase 2
	Recruiting	`NCT06129084` - A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
	Recruiting	`NCT05259319` - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)	Phase 1
	Completed	`NCT02030067` - Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies	Phase 1/Phase 2
	Active, not recruiting	`NCT02989584` - A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer	Phase 1/Phase 2
	Completed	`NCT04200963` - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma	Phase 1
	Terminated	`NCT03498196` - A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer	Phase 1/Phase 2
	Not yet recruiting	`NCT01814150` - The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel	N/A